Living well with asthma: supporting self care

A pilot Randomised controlled trial (RCT) of Asthma Internet Self management INtervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78556552

Enrollment

Registered

2013-06-18

Start date

2013-09-23

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma self management Respiratory Asthma

Interventions

Participants are randomised to two groups: 1. One group receives an internet-based resource which aims to promote adherence to asthma treatments by challenging negative beliefs, promoting activation,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Age 16 years or older 3. Diagnosis of asthma by a health professional and duration of asthma symptoms for more than 1 year 4. Juniper ACQ score = 1 5. Ability to access the internet

Exclusion criteria

Exclusion criteria: 1. Unstable asthma 2. Presence of active lung disease other than asthma 3. Mental impairment/language difficulties making informed consent impossible 4. Terminal illness 5. Cognitive impairment

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 13/02/2014: 1. Recruitment and retention rates at 12 weeks from baseline 2. Web use over 12 weeks (via automatically collected counts of access to website) plus perceived barriers and facilitators to sustained use of resource (via qualitative evaluation) 3. Changes at 12 weeks from baseline for: 3.1. Asthma Control Questionnaire (ACQ) 3.2. Asthma Quality of Life Questionnaire (AQLQ) Previous primary outcome measures: 1. Recruitment and retention rates at 12 weeks from baseline 2. Web use over 12 weeks (via automatically collected counts of access to website) plus perceived barriers and facilitators to sustained use of resource (via qualitative evaluation)	—

Measure

Time frame

Current primary outcome measures as of 13/02/2014: 1. Recruitment and retention rates at 12 weeks from baseline 2. Web use over 12 weeks (via automatically collected counts of access to website) plus perceived barriers and facilitators to sustained use of resource (via qualitative evaluation) 3. Changes at 12 weeks from baseline for: 3.1. Asthma Control Questionnaire (ACQ) 3.2. Asthma Quality of Life Questionnaire (AQLQ) Previous primary outcome measures: 1. Recruitment and retention rates at 12 weeks from baseline 2. Web use over 12 weeks (via automatically collected counts of access to website) plus perceived barriers and facilitators to sustained use of resource (via qualitative evaluation)

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 13/02/2014: 1. Changes at 12 weeks from baseline for 1.1. EQ-5D3 1.2. Patient Activation Measure (PAM) 1.3. Morisky Medication Adherence Scale (MMAS) 1.4. Lung function (via pre bronchodilator spirometry) 1.5. Airway inflammation (via fractional exhaled nitric oxide) 2. Problematic Experiences of Therapy Scale (PETS) in those in intervention group at follow up visit only (at 12 weeks) 3. Self-reported health care utilisation 4. Self-reported medication utilisation 5. Adverse events Previous secondary outcome measures: 1. Changes at 12 weeks from baseline for: 1.1. Asthma Control Questionnaire (ACQ) 1.2. Asthma Quality of Life Questionnaire (AQLQ) 1.3. EQ-5D3 1.4. Patient Activation Measure (PAM) 1.5. Morisky Medication Adherence Scale (MMAS) 1.6. Lung function (via pre bronchodilator spirometry) 1.7. Airway inflammation (via fractional exhaled nitric oxide) 2. Problematic Experiences of Therapy Scale (PETS) in those in intervention group at follow up visit only (at 12 weeks) 3. Self-reported health care utilisation 4. Self-reported medication utilisation 5. Adverse events	—

Measure

Time frame

Current secondary outcome measures as of 13/02/2014: 1. Changes at 12 weeks from baseline for 1.1. EQ-5D3 1.2. Patient Activation Measure (PAM) 1.3. Morisky Medication Adherence Scale (MMAS) 1.4. Lung function (via pre bronchodilator spirometry) 1.5. Airway inflammation (via fractional exhaled nitric oxide) 2. Problematic Experiences of Therapy Scale (PETS) in those in intervention group at follow up visit only (at 12 weeks) 3. Self-reported health care utilisation 4. Self-reported medication utilisation 5. Adverse events Previous secondary outcome measures: 1. Changes at 12 weeks from baseline for: 1.1. Asthma Control Questionnaire (ACQ) 1.2. Asthma Quality of Life Questionnaire (AQLQ) 1.3. EQ-5D3 1.4. Patient Activation Measure (PAM) 1.5. Morisky Medication Adherence Scale (MMAS) 1.6. Lung function (via pre bronchodilator spirometry) 1.7. Airway inflammation (via fractional exhaled nitric oxide) 2. Problematic Experiences of Therapy Scale (PETS) in those in intervention group at follow up visit only (at 12 weeks) 3. Self-reported health care utilisation 4. Self-reported medication utilisation 5. Adverse events

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026